Epidemiology Insights:

1) Incidence and Prevalence of Glioblastoma multiforme (GBM): Glioblastoma multiforme (GBM) is one of the most common and aggressive forms of primary brain tumors

• GBM accounts for 14.5% of all central nervous system (CNS) tumors and 48.6% of all malignant CNS tumors.
• Despite advancements in treatment, the median overall survival (mOS) for GBM patients is approximately 15 months.
• In the U.S., the incidence of glioblastoma is estimated at 3.21 cases per 100,000 people.
• Globally, GBM prevalence ranges between 0.6 and 5.0 cases per 100,000 individuals.

2) Glioblastoma multiforme (GBM) Prevalence by Age: Glioblastoma multiforme is predominantly an age-related disease

• GBM is most frequently diagnosed in older adults, with a median age of 64 years at diagnosis.
• The incidence rises with age, peaking between 75 and 84 years, before declining slightly in those aged 85 and older.
• Among adults aged 65 and above, the incidence rate reaches 130 cases per million people.
• GBM is rare in children, representing about 3% of all pediatric brain tumors and 10-15% of malignant brain tumors in the pediatric population.

3) Glioblastoma multiforme (GBM) Prevalence by Gender: Research consistently shows a higher prevalence of GBM in males compared to females.

• Across all age groups, males are more likely to develop glioblastoma than females.
• In the U.S., the male-to-female incidence ratio is approximately 1.6:1.
• A 2023 study published in the Asia Journal of Oncology reported a 2:1 male-to-female ratio, further highlighting the gender disparity in GBM cases.

4) Glioblastoma multiforme (GBM) Prevalence by Ethnic and Racial Differences: Glioblastoma multiforme incidence also varies by racial and ethnic background.

• Non-Hispanic White individuals have the highest reported incidence, at 3.51 cases per 100,000 persons.
• Asians and Pacific Islanders have the lowest incidence, with 1.18 cases per 100,000 persons.

Treatment Landscape of Glioblastoma Multiforme Treatment Market: 

GBM remains hard to cure, but innovations like Optune Gio, targeted therapies, and a growing pipeline are driving hope and market growth.

To Get more Insights,  Request A Free Sample 

There is no curative treatment for glioblastoma multiforme. Existing therapies focus on prolonging survival and improving quality of life (QoL) for patients. The standard treatment protocol typically begins with surgical resection to remove as much of the tumor as possible. However, complete removal is often unachievable due to the tumor’s invasive growth into surrounding brain tissue.

Following surgery, patients generally undergo a combination of radiation therapy and chemotherapy to target any remaining cancer cells. Temozolomide, approved by the FDA in 1999, remains the gold standard chemotherapy drug for GBM. Despite such comprehensive treatment strategies, ~90% of patients experience tumor recurrence within two years.

Treating GBM remains a significant challenge, with limited commercially available drug options. One of the most widely used targeted therapies is Bevacizumab (Avastin), approved in 2009. Avastin has become a mainstay in recurrent GBM treatment, as it helps slow disease progression. In 2024, Avastin’s total annual sales across approved indications (including GBM), reached approximately USD 1.5 billion. It continues to be a preferred choice among oncologists, especially in managing recurrent GBM cases.

In recent years, innovative technologies have entered the glioblastoma treatment (GBM) landscape. One of the most notable advancements is Novocure’s Optune Gio - a portable, wearable device that delivers Tumor Treating Fields (TTFields) to disrupt cancer cell division. Optune Gio represents a major leap forward in non-invasive GBM therapy, with a strong potential to enhance quality of life and treatment adherence. In 2024, the major markets for Optune Gio were the United States (~8,200 eligible patients), Germany (~2,500 eligible patients), and Japan (~1,200 eligible patients). The widespread adoption of this device is supported by favorable reimbursement policies. Optune Gio has received national reimbursement approval in Austria, France, Germany, Japan, Israel, Sweden, and Switzerland. In the U.S., it is reimbursed by many private insurers and covered under Medicare’s fee-for-service program.

While current innovation like Optune Gio offer hope, the true gamechangers in the GBM treatment market will likely be curative drugs and therapeutic vaccines. This underscores the importance of ongoing research and clinical trials.

To Get more Insights,  Request A Free Sample 

Driver: Rising Prevalence of glioblastoma multiforme is generating increasing demand for effective treatment options
Glioblastoma multiforme (GBM) is the most common type of glioma, accounting for ~54% of all glioma cases. Each year, an estimated 133,000 new cases of GBM are reported globally. The annual global incidence ranges from 3 to 5 cases per 100,000 individuals, with slightly higher rates observed in developed countries. This rising incidence indicates a growing patient pool in need of effective treatment solutions.

GBM remains incurable, with a median survival rate under 2 years. Due to the poor prognosis, even modest improvements in overall survival (OS) are considered significant in GBM treatment outcomes. With approximately 90% of patients experiencing recurrence, there is a critical need for more effective and durable therapeutic options. The development of curative therapies remains a key success factor in the evolving GBM treatment landscape.

To support innovation and drug development, research funding plays a vital role. Between 2000 and 2023, the National Institutes of Health (NIH) allocated USD 1.6 billion toward neuro-oncology research, with GBM accounting for 54% of the total funding.

The increasing incidence of GBM is placing pressure on pharmaceutical companies to enhance treatment effectiveness. This urgency, coupled with substantial government research funding, is accelerating the development of innovative therapies to address the unmet needs of GBM.

Challenges:High Treatment Costs and Regulatory Barriers Limiting GBM Market Expansion

The advancement of glioblastoma multiforme (GBM) therapies has introduced promising modalities such as targeted therapies, tumor treating fields (TTFields) devices, and multi-modal treatment combinations. However, the high cost of these therapies continues to be a significant barrier to widespread adoption, especially in low- and middle-income countries (LMICs).

For instance, the cost of Optune Gio therapy without commercial insurance in the U.S. is USD 21,000 per month per patient. Similarly, the price of a 400 mg Bevacizumab (Avastin) vial is ~ USD 23,000. These price points severely restrict accessibility outside high-income countries and pose reimbursement challenges even in developed healthcare systems.

Adding to the burden is the complex and time-consuming regulatory approval process for new glioblastoma multiforme (GBM) treatments. Regulatory agencies such as the FDA (U.S.) and EMA (Europe) require extensive clinical evidence demonstrating improved overall survival (OS) or progression-free survival (PFS). This metric is difficult to achieve due to the short median survival duration, high recurrence rates, and unpredictable treatment response in GBM. 

PubMed research indicates that only 8-11% of the newly diagnosed GBM patients enroll in clinical trials. Moreover, of all phased clinical trials, there are only 3-4% of the trials in phase III. Amongst these phase III trials >1% enjoy success. 

Conclusively, manufacturers face multi-million-dollar R&D costs with no guaranteed return, contributing to slower innovation cycles and limited therapy availability on a global scale.

Opportunity: Glioblastoma Vaccines as a Frontier

Glioblastoma Multiforme (GBM) remains one of the fastest-growing brain tumors that poses serious treatment challenges and often leads to poor outcomes, but recent advances in vaccine-based immunotherapy are opening promising new avenues for treatment. Several vaccine candidates, including peptide vaccines, dendritic cell (DC) vaccines, and mRNA vaccines, are currently in the research. 

Peptide vaccines can be tailored for each patient and work by stimulating the immune system to recognize and destroy tumor cells presenting specific neoantigens (SurVaxM by Mimiva). 

Dendritic cell (DC) vaccines have the potential to be incorporated in 1L treatment. DC vaccines have shown slightly better two-year overall survival (OS) rates when administered after temozolomide (TMZ) chemotherapy. 

mRNA vaccines are also emerging as a powerful therapeutic option due to their ability to provoke strong and specific immune responses against glioblastoma multiforme (GBM) cells. 

Despite notable progress, further research is needed to improve vaccine delivery methods, overcome immune resistance mechanisms, and explore combination strategies with existing therapies. Overall, the growing pipeline of vaccine-based treatments can result in a significant shift in the glioblastoma multiforme treatment landscape, offering hope for more effective and personalized care in the future.

Segmentation Glioblastoma Multiforme Treatment Market

By Treatment Type: Therapies hold the largest share of the market, followed by surgical interventions

The glioblastoma multiforme treatment market is primarily segmented into surgery, therapy and tumor treating fields (TTF) devices. 

Therapies hold the largest market share due to their widespread use as both standalone and adjunct treatments. Therapies encompass a range of modalities aimed at improving survival and disease control. These include radiation therapy, chemotherapy, and targeted immunotherapy therapies. Chemotherapy typically initiates 2-4 weeks after surgery, either concurrently with or shortly after radiation therapy. It often involves temozolomide, the gold standard drug for both newly diagnosed and recurrent GBM. In inoperable cases, chemotherapy is the primary treatment. Despite aggressive chemoradiation protocols, recurrence is frequent. Upon relapses, GBM is commonly managed with targeted therapies such as bevacizumab (Avastin), often combined with lomustine for enhanced efficacy.

Adding to it, TTFields approach is another area. It is a non-invasive treatment that uses electric fields to disrupt tumor cell division and is gaining popularity. The FDA-approved Optune Gio device is the only TTFields device approved in the market. It is used with temozolomide or as a standalone in recurrent cases. In 2024, the Optune Gio was opted by 4,000+ patients globally. Optune Gio produced an annual revenue of USD 605.2 million for GBM in 2024, mounting 19% YoY increase primarily due to continued launch success in France. 

Surgery holds the second-largest market share and is typically the first line of intervention for most glioblastoma multiforme (GBM) patients. Gliadel wafer (carmustine implants) can be planted during surgery in GBM patients. This offers localized chemotherapy delivery at the tumor site. In the recurrent setting, only about 25% of patients are eligible for repeat surgery, which limits its role and underscores the importance of non-surgical treatment strategies.

Therapy Segment by Dosage Form: Amongst therapy segment, oral formulations hold the largest share

Oral therapies currently dominate the glioblastoma multiforme treatment market, holding a majority market share. This is primarily driven by the widespread use of temozolomide (Temodar), the standard first-line treatment for newly diagnosed glioblastoma multiforme (nd GBM) in adults. Temozolomide is administered concomitantly with radiotherapy, followed by maintenance treatment as monotherapy. It is available in oral capsule form, with a cost of approximately $187 for a 5-capsule supply of 20 mg. Its established role as the initial treatment of choice has firmly positioned oral formulations in the glioblastoma multiforme treatment landscape. In addition, lomustine (Gleostine) further supports the dominance of oral therapies. Lomustine is an approved option for the treatment of recurrent glioblastoma multiforme (GBM). It is also administered orally, with a cost of approximately $658 for a 5-capsule supply of 10 mg.

Injectables hold the second largest market share with bevacizumab (Avastin) being the primary contributor. Bevacizumab is typically used in patients with recurrent or relapsed glioblastoma multiforme (GBM) and plays a critical role in managing disease progression in these advanced stages. In 2024, Avastin generated over USD 1 billion in global revenues across indications, including glioblastoma multiforme (GBM). 

Currently, the implants segment is estimated to have the least market share. However, there is estimated to increase during the forecast. It is estimated to grow with the highest CAGR owing to growing adoption because of targeted delivery of the therapeutic compound. 

By End Users: Hospitals and clinics hold the largest segment

The end-user market is segmented into hospitals and clinics, cancer centers, and academic and research organizations. Hospitals and clinics currently hold the largest share of the market, owing to their comprehensive capabilities in delivering cancer care. They have over 50% of the market share. These facilities are typically well-established and equipped to manage the full spectrum of treatment, from diagnosis to recovery, while also addressing comorbidities through a multidisciplinary approach. Their access to advanced medical technologies, surgical expertise, and capacity for inpatient care positions them as the backbone of cancer treatment services.

At the same time, cancer centers are emerging as specialized providers, offering more focused and personalized oncology care. As of October 2024, there were approximately 538 cancer treatment centers operating across the U. S. These centers deliver a wide range of services, including advanced treatment modalities. Their growing appeal lies in their patient-centric care models, cost-effectiveness, and specialization in cancer management. Currently, they hold 40% of the market. 

The lowest market share is held by academic and research organizations; they hold less than 10% of the market share. 

 To Understand More About this Research:  Request A Free Sample 

By Region: North America takes the lead, with Europe following closely behind

By region, the market is segmented into North America, South America, Europe, Asia-Pacific, and the Middle East & Africa. North America currently dominates the glioblastoma multiforme treatment market, holding the largest share due to its advanced healthcare infrastructure and strong emphasis on R&D. The region leads clinical trial activity and research investment. For instance, the Consolidated Appropriations Act of 2024 allocated USD 10 million to establish a dedicated Glioblastoma Research Program (GBMRP) under the Congressionally Directed Medical Research Programs (CDMRP). Additionally, in Canada, the Lundin Cancer Fund contributed USD 4 million in January 2025 to the Canadian Cancer Society to launch a pan-Canadian Glioblastoma Research Program, further reinforcing North America’s leadership in the space.
 
Following North America, Europe emerges as a strong player in the glioblastoma multiforme treatment market. The region is increasingly recognizing the urgency of tackling this aggressive form of brain cancer, with several countries establishing robust national research programs. For example, Germany is at the forefront with the UNITE Glioblastoma initiative, which is funded under the prestigious Collaborative Research Centers program by the German Research Foundation (Deutsche Forschungsgemeinschaft). Such efforts demonstrate Europe's growing commitment to innovation and collaboration in glioblastoma research.

Building on this momentum, the Asia-Pacific region is also making notable strides, although its funding landscape is more diverse and still emerging. Governments, national research councils, academic institutions, and private foundations are increasingly investing in glioblastoma multiforme research. A prime example is Delytact, the world’s first approved oncolytic virus therapy for malignant glioma, including glioblastoma, received conditional approval in Japan based on positive Phase 2 trial results, highlighting the region's growing contribution to clinical innovation.

Meanwhile, the Middle East and Africa remain in the early stages of developing a structured approach to glioblastoma multiforme research. However, foundational efforts are underway, led by university-affiliated research centers, private healthcare institutions, and international collaborations. These early initiatives are crucial for establishing long-term research capabilities and building regional capacity.

Recent Developments in Glioblastoma Multiforme Treatment Market

1) Laminar pharma announces promising result for lam561 in glioblastoma trial

• March 5th, 2025, Laminar Pharma announced positive results from its ongoing Phase 2b/3 trial (NCT04250922) of LAM561 in newly diagnosed glioblastoma (nd GBM) patients. The randomized, double-blind, placebo-controlled study evaluates LAM561 combined with standard chemoradiotherapy (radiotherapy + temozolomide).
• Early data show a positive trend in progression-free survival (PFS) in patients with MGMT-methylated tumors compared to placebo.
• The trial is partly funded by the EU H2020 ClinGlio project.

2) Sapience Therapeutics Presents Positive Phase 2 Data for Lucicebtide in Glioblastoma at ASCO 2025

• June 2nd, 2025, Sapience Therapeutics announced updated positive clinical and biomarker data from its ongoing Phase 2 trial of Lucicebtide (formerly ST101: NCT04478279).
• The results showcased Lucicebtide differentiated and promising therapeutic approach for GBM patients.
• In the newly diagnosed combination cohort (n=9) with data cut-off date as May 06’25; 5/9 did not experienced disease progression (10-24+ months) and 6/9 were alive (10-26+ months)
• Furthermore, in the recurrent cohort – 4/9 experienced disease control with 2 partial responses and 3/9 were alive
• Lucicebtide monotherapy and combination with SoC is well-tolerated. It crossed the blood-brain barrier and demonstrated an uptake into the tumor

Spanios and GlioGuard Announce Strategic Partnership to Accelerate Glioblastoma Drug Development

• On 1st April 2025, Spanios and GlioGuard entered a strategic partnership to advance GBM drug development by using patient-derived tumoroid platforms that closely mimic human tumors.
  • Spanios enables human-on-human efficacy testing for better therapeutic evaluation.
  • GlioGuard integrates these New Approach Methodologies (NAMs) into the drug discovery process to enhance preclinical relevance and improve patient selection strategies

Key Competitors

• Novocure
• Eisai
• Roche
• Merck & Co.
• Novartis
• Daiichi Sankyo
• Laminar pharmaceuticals
• Vigeo therapeutics
• Eli lily
• Incyte corporation
• Kazia Therapuetics
• TVAX Biomedicals

Segmentation: Glioblastoma Multiforme Treatment Market

By Treatment Type

• Surgery (Gliadel wafer)
• Therapy
  • Chemotherapy
    • Temzolomide
    • Lomustine
  • Radiation Therapy
  • Targeted Therapy (Bevacizumab)
  • Others (Delytact)
• Tumor Treating Fields (TTF) (Optune Gio)

Therapy Segment By Dosage Form

• Oral
• Injectables
• Implant

By End Users

• Hospitals & Clinics (specialty clinics)
• Cancer Treatment Centers
• Academic and Research Organizations

By Region

• North America
• South America
• Europe
• Asia Pacific
• Middle East and Africa